Navigation Links
Kuvan Receives Priority Review Status From Health Canada
Date:6/10/2009

is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the continued development and commercialization of Kuvan and BioMarin's other products and product candidates and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, Health Canada and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Kuvan Receives Marketing Approval in the European Union
5. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Athena San Diego, an organization that ... in San Diego’s technology and life science sectors, will ... at their Gala on April 30, 2015 from 5-9pm ... http://athenasd.org/events/ , The Pinnacle Awards recognize individuals ... vision of fostering networking, risk taking and diversity of ...
(Date:4/23/2015)... 23, 2015 Six startups from ... April 4-17 as part of the U.S.-Russia Innovation ... group of biotechnology startups to participate in the ... (UNN) and the University of Maryland (UMD) signed ... their respective universities in the biomedical industry in ...
(Date:4/23/2015)... Calif. , April 23, 2015  Cryoport, ... advanced cryogenic logistics solutions for the life sciences ... established its cryogenic logistics solutions within the animal ... with Yancey Farms to support the shipment of ... German Sport horse Stallions. Animal ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 ... in Personalized Medicine, is excited to announce the ... profile . This profile assesses 62 genetic variations ... dosing information for commonly prescribed non-opioid pain medications, ... name Neurontin), alprazolam (brand name Xanax) and acetaminophen ...
Breaking Biology Technology:Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3
... CoreLab Partners, Inc , the global entity resulting ... in February of this year, has launched a full ... as it relates to Dual Energy X-Ray Absorptiometry ( ... that we have formally launched state-of-the-art imaging solutions to ...
... Physicists at the University of California, Riverside have taken an ... achieving "tunneling spin injection" into graphene. An electron ... This spin comes in two forms electrons are said ... allows for more data storage than is possible with current ...
... Inc. (Nasdaq: SQNM ) today announced ... focusing on retinal diseases and conditions. The initial ... and Sequenom Center for Molecular Medicine (Sequenom CMM) ... (Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO ) ...
Cached Biology Technology:CoreLab Partners Launches New DXA Imaging Service Offerings 2UC Riverside physicists pave the way for graphene-based spin computer 2UC Riverside physicists pave the way for graphene-based spin computer 3Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 2Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 3Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 4Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 5
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... threatened with extinction around the globe, efforts to save ... conservation: a chance for complete recovery, according to health ... other members of the Blue Iguana Recovery Program. ... the Blue Iguana Recovery Programa consortium of local and ...
... French . Some of the human X ... outside Africa, according to an international team of researchers led ... University of Montreal and the CHU Sainte-Justine Research Center. The ... Biology and Evolution. "This confirms recent findings ...
... men and women in England and over a third of ... diabetes and heart disease and can significantly shorten a person,s ... journal International Journal of Behavioral Nutrition and Physical Activity ... of weight loss programs based on diet and exercise. ...
Cached Biology News:Grand Cayman blue iguana: Back from the brink of extinction 2Genetic research confirms that non-Africans are part Neanderthal 2'Love your body' to lose weight 2
... . The sensitive conductivity detector CE 4710, ... the measuring cell in a thermostatted environment. ... Data processing is provided by the CE 4900 ... high pressure CE 4100 dual piston pump. ...
... media and other fluid sources for 4 ... speed of each individual pump is controlled ... are exactly maintained. ,High-precision controlled peristaltic ... types, which allows flow rates between 0.01 ...
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... for the fast and simple integration of ... position (for the generation of transgenic mouse ... to allow neomycin / kanamycin selection in ... prokaryotic promoter (gb2) for expression of kanamycin ...
Biology Products: